TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04955301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming intervention
Description: The priming manipulation will be embedded in one discrete choice experiment to test the effect of three priming interventions: priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively, on consumers' preference for sustainable foods, and the relative importance of proximal attributes (e.g. taste and price) and distant attributes (e.g., attributes related to environmental sustainability) in determining food choice preference, as well as testing whether the effects of these three priming interventions can be modified by consumers' social orientation values. The cueing manipulation will be achieved by asking participants to complete a word-search exercise.
Study: NCT06180876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: continuous infusion
Study: NCT06087731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (8mg/kg) every 4 wekks
Study: NCT04961567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT06543940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: vancomycin dose is 7.5 to 10 mg/kg
Study: NCT05164263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
Study: NCT05887089

Intervention type: OTHER
Intervention: drone transport
Description: additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
Study: NCT05157958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-SHEET
Description: Weekly administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Control
Description: Weekly administration
Study: NCT05832567

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Subjects will undergo repetitive transcranial magnetic stimulation, each session lasting 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Subjects will undergo sham repetitive transcranial magnetic stimulation, each session lasting 20 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Open Placebo
Description: The open placebo will consist of an inactive substance pill commonly used in clinical trials and given to the subject in a regular pill dispenser.
Study: NCT06227013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whistleblowing intervention
Description: the participated nurses will receive session about Whistleblowing
Study: NCT05508464

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: SABR
Description: SABR to all tumors 6 Gy x 5 over three weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Standard of Care
Description: Standard of care palliative radiotherapy
Study: NCT06072365

Intervention type: OTHER
Intervention: nutritional intake questionnaire
Description: patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
Study: NCT05588908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (phase II)
Description: Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
Study: NCT04771663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger
Description: The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing a mixture of O2, N2 and CO2 and monitoring SpO2 on each finger
Description: The experiment consists of two separate phases. In one phase, the volunteers inhale one of the mixtures for five minutes. After enough time of recovery, the volunteers undergo the other phase in which they inhale the other mixture of gases. Both phases of the measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of both volunteer hands throughout the experiment.
Study: NCT05201352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil + XB2001
Description: trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trifluridine/tipiracil + placebo
Description: trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
Study: NCT04300140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batiraxcept
Description: Batiraxcept is experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (Cabo)
Description: Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (Cabo)
Description: Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (Cabo)
Description: Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is standard of care in the first line treatment of ccRCC
Study: NCT06367855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: long-acting corticosteroid IV route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline
Study: NCT04731337

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the tip of the upper and lower canine teeth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the tip of the upper and lower canine teeth.
Study: NCT06024889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
Study: NCT04783714

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Nutra+ Cholesterol Balance
Description: Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
Study: NCT04976322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol
Description: Subjects will receive dapirolizumab pegol at prespecified time-points.
Study: NCT05086315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443579
Description: Powder for solution for infusion; by IV infusion
Study: NCT04956432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640 Dose 1 ,tablets, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300mg, tablets, QD
Study: NCT04016818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast-dedicated PET camera
Description: Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
Study: NCT05046301

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: OTHER
Intervention: Contrast Agent
Description: Given IV

Intervention type: PROCEDURE
Intervention: Contrast-Enhanced Mammography
Description: Undergo contrast-enhanced mammography

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06323980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Total Shoulder
Description: Uncemented Reverse Total Shoulder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Total Shoulder
Description: Uncemented Reverse Total Shoulder
Study: NCT04499781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS II mHealth Intervention
Description: Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACCESS II control condition
Description: Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
Study: NCT06228625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Group
Description: * Wand Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep.)~* Codmann Exercises (In each direction with front-back, right-left, clockwise and counterclockwise movements \*10 rep.)~* Finger Ladder (flexion and abduction directions \* 10 rep.)~* Strengthening Exercises (Shoulder flexion, abduction, extension, external, internal rotation \*10 rep).~* Posterior, anterior and inferior capsule stretching ,pectoral muscle stretching \* 10 rep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Awareness Training Group
Description: * Supine: Body scan, contraction-relaxation exercises, strength recovery exercises combined with sound, stretching exercises, cross and star stretching.~* Sitting: Teaching the correct body alignment while sitting, exercise to restore the correct body alignment,~* Standing: Weight bearing exercises within stability limits, midline descent and elevation exercises, midline rotation exercises, wave motion, pushing movement combined with oblique weight bearing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitative Game Exercise Group
Description: * Cone Knockout: The game requires touching the cones that appear alternately on the right and left within one minute.~* Space Pong: It is required to play by hitting the ball with the right or left hand. It requires only upper extremity use and has seven abductions. Scoring is based on the ball hit.~* Reaction: It is a game that requires touching the green dots that appear on the screen within a certain period. The points received vary depending on the speed of touching the dots. Points are lost when the red dots are touched.~* Whack A Male: The player has 3 rights, and it requires using the upper extremity to hit the moles that come out of 5 holes at different times. A mole with a thorn on its head and a bomb should not be hit. Before the spiny mole emerges, a red light appears in the hole where it will emerge.
Study: NCT04908865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered.
Study: NCT05075122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim for Injection
Description: 75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
Study: NCT04908865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy will be continued.
Study: NCT06557876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation by pulse field ablation
Description: Pulse Field Ablation (PFA) is a non-thermal energy based on high voltage, ultra-short energy pulses applied selectively to cardiomyocytes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation by cryoablation
Description: Cryoablation is a conventional thermal energy, also delivered with a single-shot cryoballoon device.
Study: NCT06637800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
Description: The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
Study: NCT06639828

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
Study: NCT05410509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-arterial embolization (TAE)
Description: Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
Study: NCT05075122

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab injection
Description: 200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: 200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
Study: NCT05304273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Participants with 1st trimester miscarriage will receive for medical termination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants with 1st trimester miscarriage will receive for medical termination
Study: NCT05996471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH3810109
Description: VH3810109 will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VH3810109
Description: VH3810109 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir
Description: Cabotegravir will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir
Description: Cabotegravir will be administered.
Study: NCT05969145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application of thermophor
Description: The experimental group will be given hot and cold application to the bladder
Study: NCT05996471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Pre-baseline SOC antiretroviral therapy (ART) will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered.
Study: NCT06554522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Description: Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)
Study: NCT05989841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Guide
Description: Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Control
Description: Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention.
Study: NCT06249165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Study: NCT04634513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: strain CVD 1208S-122
Description: Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: strain CVD 1208S-122
Description: Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: strain CVD 1208S-122
Description: Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: strain CVD 1208S-122
Description: Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate buffer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate buffer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate buffer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate buffer